Donovan B. Yeates
CEO at KAER Biotherapeutics Corporation
Donovan B. Yeates, Ph.D., CEO, KAER Biotherapeutics Corporation, is an internationally recognized authority in aerosol drug delivery and respiratory function. Has developed technologies to deliver aerosols to the lungs, quantify the dose delivered and evaluate the physiological mechanisms whereby they are cleared from the lungs. He is an inventor of aerosol generation and delivery technology to deliver fine particle solid-phase aerosols from viscous solutions at high dose rates. Dr. Yeates is an emeritus professor with over 90 publications and 16 patents. He has a Ph.D. in Medical Biophysics from the University of Toronto.
Title: Delivery of Therapeutic Aerosols to Critically Ill Patients
- The delivery therapeutically relevant doses of anti-infectives, surfactant and anticancer agents to the peripheral lung in patients with serve respiratory impairment has been a recalcitrant issue in both spontaneously breathing patients and those on respiratory support. The issues of lung congestion, respiratory insufficiency and device interaction will be introduced
- A decision tree will be presented that addresses the issues related to the choice of aerosol delivery device suitable for critically ill patients. This will include the delivery of aqueous and solid-phase aerosols. Attention will be given to the device-patient interface
- The development of new device technologies and patient interfaces as well as the potential of heliox to improve aerosol generation, delivery and peripheral deposition will be presented